financetom
Business
financetom
/
Business
/
PM SVANidhi scheme to continue till December 2024
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PM SVANidhi scheme to continue till December 2024
Apr 27, 2022 9:47 AM

The Centre on Wednesday approved the continuation of the Prime Minister Street Vendor's AtmaNirbhar Nidhi (PM SVANidhi) scheme till December 2024, according to an official statement.

The approval was given by the Cabinet Committee on Economic Affairs chaired by Prime Minister Narendra Modi, the statement said, adding that through PM SVANidhi, affordable collateral-free loans are given to street vendors.

Also Read

| Cabinet approves Rs 820 crore financial support for India Post Payments Bank

"Today's approval has increased the loan amount to Rs 8,100 crore, thereby providing the street vendors working capital to further expand their business and making them AtmaNirbhar," the statement said.

The budget for the promotion of digital payments, including cashback to the vendors, has also been enhanced. The approval is expected to benefit nearly 1.2 crore people in urban India, the Centre said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amicus Therapeutics Reports Preliminary Q4 Revenue
Amicus Therapeutics Reports Preliminary Q4 Revenue
Jan 13, 2025
04:15 AM EST, 01/13/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) on Sunday reported preliminary Q4 revenue of $149.9 million. Analysts polled by FactSet expect $147.5 million. For full-year 2025, the company expects revenue to grow between 17% and 24% at a constant exchange rate. The company also projects positive net income for the second half of 2025. ...
Natera Says Preliminary Q4 Revenue Up 52%
Natera Says Preliminary Q4 Revenue Up 52%
Jan 13, 2025
04:12 AM EST, 01/13/2025 (MT Newswires) -- Natera ( NTRA ) reported Sunday its preliminary Q4 revenue increased 52% year over year to about $472 million. Analysts surveyed by FactSet expect $417.4 million. The company said roughly 792,800 tests were processed in Q4, compared with 626,800 tests a year earlier, marking an increase of 26.5%. ...
Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand
Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand
Jan 13, 2025
04:07 AM EST, 01/13/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Sunday its preliminary fiscal Q4 revenue is expected to increase by about 366% to $63 million, driven by the demand for Zoryve, a skin disease treatment. Analysts surveyed by FactSet expect revenue of $56.5 million. Meanwhile, full-year product revenue is expected to be about $160 million, up...
RxSight Reports Preliminary Q4 Revenue, Issues 2025 Outlook
RxSight Reports Preliminary Q4 Revenue, Issues 2025 Outlook
Jan 13, 2025
04:00 AM EST, 01/13/2025 (MT Newswires) -- RxSight ( RXST ) said Sunday it expects Q4 revenue of about $40.2 million, up roughly 41% from a year earlier. Analysts polled by FactSet expect $40.4 million. The company anticipates full-year 2024 revenue of $139.9 million. Analysts surveyed by FactSet expect $140 million. For full-year 2025, RxSight ( RXST ) expects revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved